SCHEMBL19902293

SCHEMBL19902293

CC(C)(C)OC(=O)N[C@H]1CC[C@H](c2n[nH]c(=O)c3ccccc32)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 3/20 0.49
JAK2 O60674 2/20 0.49
TYK2 P29597 1/20 0.49
JAK3 P52333 1/20 0.49
KDM1A O60341 1/20 0.47
MAOB P27338 1/20 0.47
PARP1 P09874 1/20 0.45
EPHX2 P34913 1/20 0.44
BTK Q06187 2/20 0.43
DRD2 P14416 3/20 0.42
ROCK2 O75116 2/20 0.42
ROCK1 Q13464 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19902295 1.00 JAK1 (0.49) JAK1JAK2TYK2JAK3KDM1A
SCHEMBL19902296 1.00 JAK1 (0.49) JAK1JAK2TYK2JAK3KDM1A
SCHEMBL17452520 0.86 ROCK2 (0.57) JAK1JAK2TYK2JAK3KDM1A
SCHEMBL17452517 0.86 ROCK2 (0.57) JAK1JAK2TYK2JAK3KDM1A
SCHEMBL19902689 0.81 ROCK2 (0.46) ROCK2ROCK1ALDH1A1CYP1A2CYP3A4
SCHEMBL19902690 0.81 SMN1; SMN2 (0.44) PARP1BTKDRD2ROCK2ROCK1
SCHEMBL19902322 0.80 PARP1 (0.43) JAK1JAK2KDM1AMAOBPARP1
SCHEMBL19902318 0.80 ROCK1 (0.55) JAK1JAK2TYK2JAK3PARP1
SCHEMBL20229515 0.79 PARP1 (0.42) JAK1JAK2KDM1AMAOBPARP1
SCHEMBL19902393 0.78 ROCK2 (0.41) PARP1ROCK2ROCK1ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 JAK1 461/4885JAK2 1072/4885TYK2 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.